| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 5g |
|
||
| Other Sizes |
|
Methocarbamol (Robaxin; AHR85; Lumirelax; AHR-85; Metocarbamolo), a carbamate analog of guaifenesin, is a potent carbonic anhydrase inhibitor (CAI) with sedative and musculoskeletal relaxant properties. It is used as a central muscle relaxant for the treatment of skeletal muscle spasms.
| ln Vitro |
The decay periods of the EPCs and EPPs generated by phrenic nerve stimulation are markedly increased by methocarbamol (2 mM; for 20 min)[3]. Nav1.7 currents are unaffected by methocarbamol[3].
|
|---|---|
| ln Vivo |
The muscle relaxant activity of methocarbamol (200 mg/kg; ip) is 88.96%[3].
|
| Animal Protocol |
Animal/Disease Models: Mice with weight 20-30 g[3]
Doses: 200 mg/kg Route of Administration: IP; single dose Experimental Results: Had Muscle relaxant activity of 88.96%. |
| References |
[1]. Bruce, R.B., L.B. Turnbull, and J.H. Newman, Metabolism of methocarbamol in the rat, dog, and human. J Pharm Sci, 1971. 60(1): p. 104-6.
[2]. Sica, D.A., et al., Pharmacokinetics and protein binding of methocarbamol in renal insufficiency and normals. Eur J Clin Pharmacol, 1990. 39(2): p. 193-4. [3]. Yaxin Zhang, et al. Methocarbamol blocks muscular Na v 1.4 channels and decreases isometric force of mouse muscles. Muscle Nerve. 2020 Oct 11. |
| Molecular Formula |
C11H15NO5
|
|
|---|---|---|
| Molecular Weight |
241.24
|
|
| CAS # |
532-03-6
|
|
| Related CAS # |
Methocarbamol-d5;1189699-70-4;Methocarbamol-d3;1346600-86-9;Methocarbamol-13C,d3;2747917-88-8
|
|
| SMILES |
OC(COC1=CC=CC=C1OC)COC(N)=O
|
|
| Synonyms |
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 3.5 mg/mL (14.51 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 35.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 3.5 mg/mL (14.51 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 35.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 3.5 mg/mL (14.51 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 25 mg/mL (103.63 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication (<60°C). |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.1452 mL | 20.7262 mL | 41.4525 mL | |
| 5 mM | 0.8290 mL | 4.1452 mL | 8.2905 mL | |
| 10 mM | 0.4145 mL | 2.0726 mL | 4.1452 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05100017 | Recruiting | Drug: Methocarbamol Drug: Oxybutynin |
Kidney Calculi Kidney Diseases |
Northwestern University | September 30, 2021 | Not Applicable |
| NCT04458454 | Completed | Diagnostic Test: Relaxin ELISA Kit | Infertility Reproductive |
D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology |
December 2, 2019 | |
| NCT05204667 | Recruiting | Drug: 380 mg/300 mg comprimidos metocarbamol/paracetamol - 4 times daily |
Low Back Pain | Aziende Chimiche Riunite Angelini Francesco S.p.A |
October 7, 2021 | Phase 4 |
| NCT05388929 | Recruiting | Drug: Methocarbamol Drug: Standard Opioid |
Ventral Hernia Inguinal Hernia |
Prisma Health-Upstate | June 23, 2022 | Phase 4 |
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
